MediPharm Labs Achieves Pharmaceutical GMP Certification with Brazilian Health Authority
TORONTO, Feb. 7, 2024 /PRNewswire/ – MediPharm Labs Corp. (TSX:LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce receipt of GMP certification for their Barrie, Ontario facility from ANVISA, the governing body of Brazil’s pharmaceutical industry. MediPharm Labs now has GMP certification from the United States FDA, European Union, Australia’s TGA and holds a drug establishment license from Health Canada.
Related news for (MEDIF)
- MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States
- Apollo Capital Releases Investor Presentation Highlighting Plan to Make MediPharm Labs the World’s Leading International Medical Cannabis Company
- MediPharm Labs’ Founder-CEO Pat McCutcheon Throws his Support behind Apollo Capital as Dissident
- MediPharm Labs Closes $4.5 Million Sale of Hope, BC Facility and Announces Plans to Expand EU GMP Cultivation Capacity at Napanee Facility
- MediPharm Labs Refuses to Answer Direct Questions Regarding Credible Securities Fraud Allegations Says Apollo Capital